Delivery Order SPE2DB25D3504-SPE2DB25FVVED
- Not listed
- The Defense Logistics Agency awarded a $3,188.32 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 25, 2025, and is being performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 300 mg/2 mL auto-injector vials valued at $3,188.32. This firm fixed-price delivery order is scheduled for completion by August 11, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units valued at $1,594.16. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and no set-aside designation was applied. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $1,594.16 and a firm fixed price structure. The order is scheduled for completion by August 11, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under a non-set-aside, competitive procurement process and represents a continuation of the pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units with a firm fixed price ceiling value of $1,594.16 and an ultimate completion date of August 26, 2025. This non-set-aside award operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The product...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials with a firm fixed price ceiling value of $3,188.32 and an ultimate completion date of August 26, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract will be performed at...
- The Defense Logistics Agency awarded a $6,376.64 delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by July 22, 2025. The award represents a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026....
- The Defense Logistics Agency awarded a $6,376.64 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 13, 2025, for the supply of XOLAIR 300 mg/2 ml auto-injector medication. The order is scheduled for completion by July 8, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract vehicle. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials with a firm fixed price ceiling value of $3,188.32. This is a competitively awarded, non-set-aside delivery order with an ultimate completion date of August 26, 2025. AmerisourceBergen Drug Corp will perform the work at its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical...
- The Defense Logistics Agency awarded a $3,188.32 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 25, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB25D3504Indefinite Delivery Contract
- SPE2DB25D3504-SPE2DB25FVVEDDelivery Order
The Defense Logistics Agency awarded a $3,188.32 delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. The contract is classified as firm fixed price with no set-aside designation, indicating the award resulted from open competition. Performance will be completed by July 14, 2025, with fulfillment occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under a larger vehicle supporting federal medical procurement. This award falls under AmerisourceBergen's significant Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a global pharmaceutical support vehicle enabling the company to supply an extensive range of medications and medical supplies to military healthcare systems worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across multiple therapeutic domains and demonstrates substantial capacity through its competitive awards history and comprehensive product portfolio spanning specialty medications, vaccines, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 6/20/25 |